Crescendas Healthcare Group

has strategic investments in Singapore, Germany and Australia with a key focus on healthcare and biotechnology.

Singapore Institute of Advanced Medicine Holdings (SAM)

Crescendas Healthcare Group has a strategic interest in SAM. SAM operates a vertically integrated, oncology and diagnostics platform, offering patients services for the full process from health screening/GP services to diagnostic imaging to treatment. They specialise in radiotherapy and proton therapy, enabling precise and minimally invasive treatment.

Visit advancedmedicine.sg

EnGeneIC

Crescendas Healthcare Group has a strategic interest in EnGeneIC, the world’s first cancer cyto-immunotherapy with minimal toxic side effects.

Using EnGeneIC’s proprietary EDV™ nanocell technology, patients with end-stage pancreatic, glioblastoma, mesothelioma and neuroendocrine cancer have been successfully treated. As they target treating cancers with unmet needs, EnGeneIC has been placed on the FDA Fast Track pathway.

Visit engeneic.com

Hospital Asset in Germany

Crescendas Healthcare Group has acquired a hospital in Hamburg Germany with a total of 692 beds for acute care and rheumatology rehabilitation, with two more acquisitions in the pipeline. Through this acquisition, we have also established a partnership with NAVICARE-MED.